OpenEvidence is the name for both the product (an LLM) and the company, an American artificial intelligence company that develops a medical search engine, which is used by healthcare professionals for clinical decision making support. The company was founded in 2022 by entrepreneur Daniel Nadler and is headquartered in Miami, Florida. As of January 2026, the company is valued at $12 billion, following several funding rounds.
History OpenEvidence was founded in 2022 by Daniel Nadler, a Harvard Ph.D. and former founder of Kensho, a financial analytics firm acquired by S&P Global in 2018. Nadler launched the company with co-founder Zack Ziegler, a machine learning researcher from Harvard, to address the challenge physicians face in keeping up with the growing volume of medical literature. In 2023, OpenEvidence reported that its artificial intelligence model achieved a 90 percent score on the United States Medical Licensing Examination (USMLE). During the same year, the company participated in the Mayo Clinic health-technology accelerator. In 2025, the company stated that the model had reached a 100 percent score on the same examination. In February 2025, OpenEvidence raised $75 million in a Series A round led by Sequoia Capital, valuing the company at $1 billion. In July 2025, the company secured $210 million in funding from a round led by GV (Google Ventures) and Kleiner Perkins, with participation from Coatue, Conviction, and Thrive Capital. This round valued the company at $3.5 billion. In April 2025, OpenEvidence was featured in the Forbes AI 50 list. OpenEvidence has established content licensing partnerships with several medical organizations and journals, including American Medical Association, National Comprehensive Cancer Network (NCCN), American Academy of Family Physicians, American College of Emergency Physicians, New England Journal of Medicine, Journal of the American Medical Association, JAMA Network, JAMA Oncology, and JAMA Neurology. On October 20th 2025, the company announced a US$200 million Series C funding round, valuing the company at US$6 billion. As of December 2025, the company reported 760,000 registered U.S. physicians and approximately 18 million clinical consultations per month. In January 2026, OpenEvidence raised $250 million in a Series D funding round at a $12 billion valuation. As of early 2026, OpenEvidence had raised approximately $700 million in total funding from investors including Google Ventures, Nvidia, Sequoia, Blackstone, Thrive Capital, Kleiner Perkins, Craft Ventures and Mayo Clinic.
Partnerships In May 2026, OpenEvidence partnered with Cedars-Sinai to integrate its decision support platform into the hospital's electronic health record infrastructure. The integration allows healthcare professionals to query medical literature using patient-specific clinical context.
Product and technology OpenEvidence provides a Large Language Model with an artificial intelligence-based platform that analyzes and organizes peer-reviewed medical literature from clinical journals such as The New England Journal of Medicine and The Journal of the American Medical Association. According to the company, access is available at no cost to verified physicians, with revenue derived from advertising. As of July 2025, the company reported more than 430,000 registered U.S. physicians (about 40% of U.S. physicians) and use in over 8.5 million consultations per month. In the same month, OpenEvidence introduced a feature called DeepConsult, described as employing reasoning models to synthesize findings across multiple studies. In May 2026, the company introduced Voice Mode, a voice-based interface for its platform that was made available through the company's web and mobile applications. Practitioners can utilize the platform with their National Practitioner Identity numbers to create an account free of charge. When prompting an inquiry OpenEvidence will then begin referencing published medical journals to provide seemingly up to date information, and suggestion on clinical topics.
Recognition In 2025, Daniel Nadler, co-founder of OpenEvidence, was named to the TIME100 Health list of the 100 most influential people in global health.
See also Clinical decision support system Generative artificial intelligence Large Language Models (LLMs) List of open-source health software List of freeware health software
References
External links Official website


